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In Duchenne muscular dystrophy (DMD), dystrophin
mutation leads to progressive lethal skeletal muscle
degeneration. For unknown reasons, dystrophin defi-
ciency does not recapitulate DMD in mice (mdx),
which have mild skeletal muscle defects and potent
regenerative capacity. We postulated that human
DMD progression is a consequence of loss of func-
tional muscle stem cells (MuSC), and the mild mouse
mdx phenotype results from greater MuSC reserve
fueled by longer telomeres. We report that mdx
mice lacking the RNA component of telomerase
(mdx/mTR) have shortened telomeres inmuscle cells
and severe muscular dystrophy that progressively
worsens with age. Muscle wasting severity parallels
a decline in MuSC regenerative capacity and is
ameliorated histologically by transplantation of
wild-typeMuSC. These data show thatDMDprogres-
sion results, in part, from a cell-autonomous failure
of MuSC to maintain the damage-repair cycle initi-
ated by dystrophin deficiency. The essential role of
MuSC function has therapeutic implications for DMD.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is a devastating muscle
degenerative disease caused by a mutation in dystrophin (Hoff-
man et al., 1987), a cytoskeletal protein that is essential for the
stability of the membrane of multinucleated myofibers in skeletal
muscle (Durbeej and Campbell, 2002). Absence of dystrophin
results in increased fragility of the sarcolemma, leading to injuryCin the presence of even mild stress (Petrof et al., 1993). DMD
patients suffer from progressive loss of muscle function, leading
to paralysis and death in the third decade of life (Emery, 2002).
Under normal conditions, skeletal muscle is relatively quiescent
when compared to high-turnover tissues such as the blood and
most epithelia. However, skeletal muscle harbors considerable
regenerative capacity due to the presence of adult muscle
stem cells (MuSC), also known as satellite cells, which play
a major role in postnatal muscle growth and repair (Collins
et al., 2005; Cornelison et al., 2004; Kuang et al., 2007;Montarras
et al., 2005; Sacco et al., 2008). In DMD, unrelenting, recurrent
myofiber damage elicits a constant need for regeneration.
Eventually, muscle tissue is supplanted by fibrosis, calcium
deposits, and adipose accumulation that coincide with clinical
manifestations. To date, the basis for the observed mild effects
inmice and lethal effects in humans of the same genetic absence
of dystrophin remain unknown. Furthermore, although clearly
initiated by dystrophin deficiency, the pathophysiological cause
of the failure of the repair process in muscles of DMD patients is
not understood.
More than two decades ago, before the cloning of the DMD
gene, we obtained data that suggested that muscle cells in
DMDpatients have diminished regenerative capacity as a conse-
quence of replicative aging (Blau et al., 1983; Webster and Blau,
1990). Human DMD myoblasts exhibited a severe proliferation
deficit in vitro that became more pronounced with patient age,
resulting in a yield of myoblasts per gram muscle of 5% of
normal, and the proliferative potential of the remainingmyoblasts
was severely impaired. However, this proliferative defect did not
segregate with the X chromosome in studies of myoblast clones
from doubly heterozygous carriers for two X-linked loci, DMD
and a Mediterranean histologically detectable heat-labile variant
of G6PD, and was therefore dependent on additional factors
(Webster et al., 1986).ell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc. 1059
Recent studies support and extend the early findings that
myoblasts from DMD have impaired replicative potential and
suggest that telomere shortening is a common feature of dystro-
phic human muscle cells with increasing age. This correlates
with their limited ability to regenerate DMD tissues upon trans-
plant (Mouly et al., 2005). Indeed, a 14-fold greater shortening
of telomeres in DMD patients relative to healthy individuals has
been reported (Decary et al., 2000). Telomeres are DNA repeats
that protect chromosome ends from illicit recombination, fusion,
and degradation leading to genomic instability (Palm and de
Lange, 2008). Telomere length is maintained by the enzyme telo-
merase, which adds telomere repeats to chromosome ends,
ensuring their proper replication (Greider and Blackburn, 1985).
Cell proliferation in settings of insufficient telomerase results in
progressive telomere shortening, ultimately leading to replicative
senescence as chromosome end protection is compromised at
a subset of short telomeres (Rodier et al., 2005; Sherr and
DePinho, 2000). Telomere shortening also accompanies aging
of mitotically active human tissues with high turnover, including
blood, liver, skin, testis, and kidneys (Aikata et al., 2000; Friedrich
et al., 2000; Lindsey et al., 1991; Takubo et al., 2000; Vaziri et al.,
1993). In contrast, analysis of telomeres in skeletal muscle during
aging in whole-tissue assays reveals only a mild shortening
(Decary et al., 1997; Renault et al., 2002), presumably reflecting
the low rate of proliferation of myogenic progenitors and muscle
tissue turnover during normal aging. In agreement with these
findings, studies of telomerase knockout mice revealed short
dysfunctional telomeres that profoundly impaired progenitor
cell function in actively renewing tissues. This led to atrophy
and reduced regenerative potential, whereas more quiescent
low-turnover tissues such as muscle were unaffected (Allsopp
et al., 2003; Lee et al., 1998; Rudolph et al., 1999).
A major challenge hindering the development of effective ther-
apies for DMD has been the lack of an animal model that closely
recapitulates the disease progression in humans. The most
widely used animal model for DMD, the mdx mouse, exhibits
only a mild dystrophic phenotype, although like DMD patients,
it lacks functional dystrophin due to a point mutation in the dys-
trophin gene (Bulfield et al., 1984; Hoffman et al., 1987; Ryder-
Cook et al., 1988). Muscles of mdx mice, like those in DMD
patients, undergo repeated cycles of degeneration and regener-
ation, but for unknown reasons, the mice exhibit only transient
muscle weakness and never exhibit the profound loss of muscle
strength and death observed in DMD patients (DiMario et al.,
1991; Straub et al., 1997). Here, we test the hypothesis that
species-specific differences in telomere length account for the
differential proliferative capacity of muscle cells derived from
DMD patients and mdx mice and consequent disparate disease
progression between the two species. Humans have relatively
short telomeres of 5–15 kilobases in comparison to in-bred
strains of laboratory mice, which have telomeres that are typi-
cally > 40 kilobases (Kipling and Cooke, 1990). This greater telo-
mere reserve could endow MuSC in mice with a prolonged
regenerative capacity and mild muscle phenotype despite dys-
trophin deficiency. In support of this hypothesis, lack of a disease
phenotype in mouse models of other human diseases, such as
Werner and ataxia-telangiectasia syndromes, has been linked
to species-specific differences in telomere length, as when these1060 Cell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc.models were crossed with mice lacking telomerase activity, the
disease became apparent (Chang et al., 2004; Wong et al.,
2003).
Here, we generate mdx mice lacking telomerase activity
and show that dystrophin deficiency coupled with telomere
dysfunction recapitulates the severe phenotypic characteristics
of muscular dystrophy in humans, including profound loss of
muscle force, poor performance on a treadmill, increased serum
creatine kinase (CK) levels, accumulation of fibrosis and calcium
deposits within skeletal muscle tissues, kyphosis, and shortened
life span. We show that the severity of the disease progressively
worsens with age. Moreover, MuSC exhibit a severe proliferation
deficit both in vitro and in vivo, inability to respond to tissue
injury, and markedly reduced engraftment and contribution to
muscle repair. Transplantation of WT MuSC into mdx mice lack-
ing telomerase activity ameliorates the dystrophic phenotype
histologically. Together, these results indicate that the combina-
tion of the structural defect of dystrophin deficiency that leads to
muscle degeneration together with the progressive exhaustion
of functional MuSC generates the dystrophic phenotype. These
findings support the hypothesis that, in humans, DMD is initiated
by the genetic defect but, as suggested by our earlier findings
(Blau et al., 1983; Webster et al., 1986), develops progressively
into an exhaustion of cells with regenerative potential.
RESULTS
We generated dystrophic mice lacking telomerase activity by
crossing C57Bl6 mdx female mice homozygous for the dystro-
phin mutation (Im et al., 1996) with C57Bl6 mice heterozygous
for the telomerase RNA component Terc (mTR) (Blasco et al.,
1997) (Figure 1A). The resulting mdx/mTRHet mice were further
crossed to generate double-mutant mdx mice totally lacking
dystrophin and telomerase activity (designated herein as first-
generation mdx/mTRG1). The mdx/mTRG1 mice were, in turn,
intercrossed to produce second-generation mdx/mTRG2 mice.
This strategy yields the same strain of dystrophic mice that
lack telomerase, which is critical, as telomere length differs
among mouse strains (Hemann et al., 2001). In addition, the
dystrophic phenotype is analyzed in mice with different telomere
lengths, as shortening increases in mTR mice with successive
generations.
Severe Muscular Dystrophy in mdx/mTRG2 Mice
To assess the severity of muscular dystrophy, we carried out
three essential controls. We compared mdx/mTRG1 and mdx/
mTRG2 mice with mdx/mTRHet mice, as these mice lack dystro-
phin and one copy of the Terc gene, providing the most stringent
same-strain control. As a second control, we analyzed mTRG2
mice, which are generation matched for telomerase deficiency
but have wild-type dystrophin, which was essential in order to
rule out the possibility that a phenotype resulted from telomerase
deficiency alone. Finally, our studies were restricted to male
mice, as the disease is X-linked and differences in sex can
confound results.
We first tested serum creatine kinase (CK) levels, an estab-
lished indicator of skeletal muscle damage in mice that is a diag-
nostic indicator of DMD. Eight-week-old mdx/mTRG2 males
Figure 1. Evidence of Severe Muscular Dystrophy in mdx/mTRG2 Mice
(A) Scheme of mouse breeding.
(B) Serum CK levels in 8-week-old males. A marked increase in CK levels is seen in mdx/mTRG2 animals. Data are represented as average ± SEM. n R 10;
p values are indicated in the graph. See also Figure S1A.
(C) Eight-week-old males were subjected to the treadmill test, and their performance was measured as time to exhaustion. mdx/mTRG2 animals were severely
impaired in their muscle endurance, compared to WT or mdx/mTRHet. Data are represented as average ± SEM. nR 5; p values are indicated in the graph. See
also Figures S1B and S1C.
(D) Quantification of Evans blue dye uptake in diaphragmmuscle of 8-week-old nonexercisedmice (%EBD+ area). Data are represented as average ±SEM. n = 3;
p values are indicated in the graph. See also Figure S2.
(E) Representative images of Evans blue dye uptake in diaphragm muscles from the various genotypes.
(F and G) Muscle force was measured in the lateral gastrocnemius muscle in vivo in 8-week-old anesthetized animals by electrical stimulation of the sciatic nerve
and was expressed relative to cross-sectional area (P0/CSA, force per square meter, kN/m
2). Data are represented as average ± SEM. nR 4; p values are indi-
cated in the graph. See also Figure S1D.
(H) Quantification of centrally nucleatedmyofibers in gastrocnemius muscles of 8-week-old mice from the indicated genotypes. Data are represented as average
± SEM. n = 3; p values are indicated in the graph.already have remarkably elevated serum CK (7594 ± 928 IU/l),
compared to mdx/mTRHet males (1148 ± 477 IU/l) (Figure 1B),
approximating human DMD levels (6000–8000 IU/l in 10-year-
old patients) (Zatz et al., 1991). However, by 60 weeks of age,
CK levels decline in mdx/mTRG2 mice (Figure S1A available
online), consistent with CK levels in DMD patients that peak at
1–6 years of age when active muscle degeneration is occurring
and then decrease with age as muscle tissue is progressively
lost (Zatz et al., 1991). Heterozygous mdx/mTRHet mice with
increased age show increased CK levels, presumably due toCslower progression of the disease (Figure S1A). Serum CK levels
are indistinguishable for mTRG2 and healthy WTmice (Figure 1B,
p > 0.05), consistent with previous studies showing that telomere
deficiency preferentially affects highly proliferative organs, but
not skeletal muscle (Allsopp et al., 2003; Artandi, 2006; Herrera
et al., 1999; Lee et al., 1998). The progressive elevation of CK
seen in mdx/mTRG1 and mdx/mTRG2 animals suggests that
muscle damage increased with successive generations, impli-
cating telomere attrition as a cooperating factor with dystrophin
deficiency in disease manifestation.ell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc. 1061
Figure 2. Histological Evidence of Severe Muscular Dystrophy in Muscles from mdx/mTRG2 Mice
(A) Hematoxylin and eosin staining of transverse sections of diaphragm (top) and gastrocnemius (bottom) muscles from the indicated genotypes at 8 weeks of
age. Scale bar, 120 mm. See also Figure S2.
(B) Average diaphragm diameter is significantly increased in 8-week-old mdx/mTRKO mice. Data are represented as average ± SEM. n = 3; p < 0.05.
(C) Alizarin red staining to visualize calcium deposits (top) and Gomori staining for collagen deposition (bottom) in muscle transverse sections from 8-week-old
mice. Scale bar, 120 mm.Skeletal muscle damage is also evident as myofiber
membrane permeability, measured by Evans blue dye (EBD)
uptake (Straub et al., 1997). Diaphragm and gastrocnemius
muscles of 8-week-old mdx/mTRG2 male mice exhibit a signifi-
cant increase in the percentage of EBD-positive areas, com-
pared to mdx/mTRHet or mdx/mTRG1 mice (Figures 1D and 1E
and Figure S2). Control mTRG2 mice are indistinguishable from
WT mice, confirming that the absence of telomerase activity
per se is not sufficient to trigger skeletal muscle damage.
Membrane permeability significantly worsens with age, as 60-
week-old mdx/mTRG2 animals exhibit higher EBD incorporation
(Figure S2). Together, these data indicate that, in the absence of
telomerase, dystrophin deficiency causes progressive skeletal
muscle damage in mice.
To assess muscle performance, we first analyzed time to
exhaustion on a treadmill. Eight-week-old mdx/mTRG2 mice
run for a significantly shorter time than control WT (3.8 ± 0.6
versus 22.8 ± 2.6 min) or mdx/mTRHet mice (16.3 ± 3.9 min).
Muscle performance further worsens with age, as 24-week-old
mdx/mTRG2 mice barely run at all (1.1 ± 0.6 min) (Figure 1C
and Figure S1B). By contrast, age-matched mTRG2 mice are
indistinguishable from WT mice at both 8 and 24 weeks of age
(Figure 1C and Figure S1B). A second well-established assay
of muscle performance is the grid test, a measure of the length1062 Cell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc.of time that mice can support their weight by holding onto
a rod. The results of the grid test in 8-week-old mice paralleled
the treadmill experiment, as mdx/mTRG2 mice are able to
hold onto the grid for a substantially shorter time than controls
(Figure S1C). Third, we measured specific muscle force of
gastrocnemius muscles. To avoid potential artifacts due to
muscle excision, we assayed force generation in vivo in intact
muscles in 8-week-old anesthetized animals (Blaauw et al.,
2008). Lateral gastrocnemius muscle twitch force, tetanic force,
and tetanic tension are markedly decreased in mdx/mTRG1 and
further decrease in mdx/mTRG2 mice, compared to control WT,
mdx/mTRHet, and mTRG2 mice (Figures 1F and 1G and Fig-
ure S1D), providing direct evidence for progressively severe
muscle weakness.
Histologically, the percentage of centrally nucleated myofib-
ers, a hallmark of muscle regeneration, is increased in mdx/
mTRHet mice (63% ± 4%) relative to WT (0.7% ± 0.1%) but is
further increased in mdx/mTRG1 and mdx/mTRG2 muscles
(90% ± 1%) (Figure 1H and Figure 2A), providing evidence of
a marked increase in tissue damage and regenerative activity
in most fibers at 8 weeks of age. Further histological analyses
of diaphragm and gastrocnemius muscles from 8-week-old
mdx/mTRG2 mice reveal a marked increase in myofiber diameter
heterogeneity, mononuclear cellular infiltration, necrosis, and
Figure 3. Muscular Dystrophy in mdx/
mTRG2 Mice Progresses with Age
(A) Whole-body SPECT/CT images. Pronounced
skeletal deformity of the spine (kyphosis) is pre-
sent in 76-week-old mdx/mTRG2 mice, compared
to age-matched controls.
(B) Animal weight significantly decreased in
mdx/mTRG2 mice at 76 weeks of age (top).
nR 3; p < 0.05. Indicated muscles were harvested
from mice at various ages and weighed. Data are
represented as the weight of the tissue relative to
total body weight, a standard control for telomere
shortening (Lee et al., 1998). Results are shown as
average ± SEM; nR 3; p < 0.05.
(C) Kaplan-Meier survival curve. mdx/mTRG2 mice
exhibited reduced life span compared to mdx/
mTRHet and WT controls. nR 12.
(D) Hematoxylin and eosin staining of diaphragm
muscle from animals at 76 weeks of age showed
dramatic atrophy of the tissue in mdx/mTRG2
animals compared to controls. Scale bar, 120 mm.
See also Figure S3.overall altered tissue structure relative to age-matched controls
(Figure 2A). Importantly, muscle histology from mTRG2 control
mice is indistinguishable from WT mice. Diaphragm diameter
of mdx/mTRHet is increased compared to WT, consistent with
ongoing tissue damage and repair (Figures 2A and 2B) and
further increases in mdx/mTRG1 and mdx/mTRG2 mice, due
primarily to massive cellular infiltration (Figures 2A and 2B).
Aggregates of calcium deposition and fibrotic regions are
substantially increased in mdx/mTRG2 muscle (Figure 2C), by
contrast with mdx/mTRHet and mdx/mTRG1 muscles. Thus,
although the control mdx/mTRHet mice undergo substantial
muscle regeneration, as indicated by the relatively high
frequency of centrally nucleated myofibers, the tissue histology
is not compromised compared with mdx mice lacking telome-
rase activity (G1 and G2).Cell 143, 1059–1071, DeMuscular Dystrophy in mdx/mTRG2
Mice Progresses with Age
The severe progression of DMD associ-
ated with age is not recapitulated in
mdxmice. Kyphosis of the spine is a clas-
sical clinical manifestation of DMD due to
uneven weakening of trunk muscles and
substitution with connective tissue and
fat (Oda et al., 1993; Wilkins and Gibson,
1976). SPECT-CT imaging revealed that
kyphosis in a cohort of aging mice is
substantially more pronounced in mdx/
mTRG2 mice than in age-matched mdx/
mTRHet controls at 76 weeks of age
(Figure 3A).
We analyzed the severity of muscle
wasting by assessing a loss of both total
body weight and specific muscle weight
due to atrophy, which is typically exacer-
bated with increasing age in DMD
patients. Total body weight is dispropor-tionately reduced in mdx/mTRG2 mice compared to controls at
76 weeks of age (Figure 3B). When controlled for total body
weight, all genotypes exhibit a progressive decrease in muscle
weight with age, but the drop is accelerated in mdx/mTRG2
muscles after 60 weeks. In 8-week-old mice, the diaphragm
and tibialis anterior mdx/mTRG2 muscles exhibit an increase in
weight relative to total body weight (Figure 3B), consistent with
observations in DMD patients, whose body weight transiently in-
creases at young ages but then decreases at later ages due to
skeletal muscle atrophy (McDonald et al., 1995). The weight of
control testis tissue, a high proliferative organ, does not change
significantly among genotypes, indicating that the tissue atrophy
is specific to muscles (Figure S5). Kaplan-Meyer survival anal-
yses show that mdx/mTRG2 mice have reduced life span, start-
ing to die at 48 weeks of age, whereas mdx/mTRHet do notcember 23, 2010 ª2010 Elsevier Inc. 1063
Figure 4. Muscle Stem Cells from mdx/
mTRG2 Mice Exhibit Impaired Proliferation
In Vivo
(A) Eight-week-old undamaged or NTX-damaged
mice were pulsed with BrdU for 24 hr prior to
tissue harvesting. MuSC were isolated by FACS,
and immunofluorescence for BrdU (green) and
Hoechst (blue) was performed. Representative
images of MuSC from all genotypes are shown.
Arrowheads indicate BrdU+ cells. Scale bar,
80 mm. See also Figure S4.
(B) Percentage of BrdU+ MuSC represented as
average ± SEM. n R 3; p values are indicated in
the graph.
(C) Single fibers were isolated from tibialis anterior
muscles at the indicated ages and stained for
Pax7 (green) and nuclei (blue). Representative
image showing a single fiber with a Pax7+ satellite
cell (arrowhead). Scale bar, 50 mm (top). Graph
showing number of Pax7+ satellite cells/fiber.
n = 3 animals/group and 50–100 myofibers/animal.
Data are represented as average ± SEM (bottom).
(D) Representative images of transverse sections of
gastrocnemius muscles from the indicated geno-
types at 8 weeks of age immunostained for dystro-
phin (green) and nuclei (blue). Scale bar, 100 mm
(top). Graphs showing distribution of size of rever-
tant myofiber clusters (dotted lines in the graphs
represent the median of cluster size) (bottom).show a difference compared to WT animals (Figure 3C). Finally,
histological analyses of limb muscles from 76-week-old animals
reveal pronounced tissue damage in mdx/mTRG2 mice, with
extensive fibrosis and immune cell infiltration (Figure S3). Most
notably, diaphragmmuscles frommdx/mTRG2 mice at 76 weeks
of age have atrophied to a small remnant of their original size,
suggesting that respiratory failure is the cause of premature
death (Figure 3D).
Impaired Proliferation of mdx/mTRG2 MuSC in Mice
In Vivo
We hypothesized that the severe muscle phenotype observed in
mdx/mTRG2 animals is caused by defects in MuSC function. To1064 Cell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc.test this possibility, we assessed MuSC
proliferation in vivo by assaying undam-
aged or acutely notexin injured tibialis
anterior muscles (Harris and MacDonell,
1981) injected intraperitoneally with
bromo-deoxyuridine (BrdU) 24 hr prior
to harvesting. MuSC were then isolated
by FACS to > 90%purity for all genotypes
(Figure S4), as previously described
(Sacco et al., 2008), and analyzed for
BrdU incorporation. In WT mice in un-
damaged conditions, only 0.4% ± 0.2%
of MuSC were BrdU+ (Figures 4A and
4B), consistent with previous reports
that adult MuSC are largely quiescent in
steady-state conditions (Cerletti et al.,2008). However, upon notexin injury, WT MuSC are activated
and enter the cell cycle, and 8.6% ± 2.9% are BrdU+ (Figures
4A and 4B). In undamaged mdx/mTRHet mice, 2.5% ± 1.4% of
MuSC are BrdU+, which is higher than WT mice, consistent
with ongoing tissue regeneration due to dystrophin deficiency.
MuSC frommdxmice are able to respond appropriately to acute
injury by entering the cell cycle (5.1% ± 0.6%). In contrast, MuSC
frommdx/mTRG1 (1.4% ± 0.3%) andmdx/mTRG2 (1.3% ± 0.2%)
mice exhibit markedly reduced BrdU incorporation in the
absence of notexin damage (Figures 4A and 4B), which does
not significantly increase upon injury in mdx/mTRG1 (1.6% ±
0.1%) and mdx/mTRG2 mice (2.5% ± 0.4%), indicating a severe
defect in MuSC proliferation in response to tissue damage.
Figure 5. Telomere FISH Analysis in Primary Myoblasts
(A) Representative images of FISH onmetaphase spreads frommdx/mTRHet, mdx/mTRG1, andmdx/mTRG2 (red, telomeres; blue, Hoechst). Arrows show end-to-
end fusion of chromosomes, indicating genomic instability.
(B) Graph showing the quantification of percentage of chromosomeswith signal-free ends (total number of chromosomes analyzed are shown on top of each bar).
p < 0.03. See also Figure S5.
(C) Scheme representing the series of events during muscle regeneration in the mdx mouse model (left) compared to the mdx/mTRG2 dystrophic model (right).
Critical telomere shortening and chromosomal fusions in mdx/mTRG2 muscle cells result in impaired ability to sustain tissue regeneration.Of note, proliferative MuSC behavior from control mTRG2 mice is
not impaired and is indistinguishable from WT mice. These data
highlight that MuSC become severely impaired when the
absence of dystrophin is combined with the absence of telome-
rase activity.
The number of Pax7+ satellite cells per myofiber (8.7 ± 0.6 in
WT, 7.7 ± 0.1 in mdx/mTRHet, and 8.5 ± 0.8 in mdx/mTRG2) is
not statistically different among the different genotypes (p >
0.05) (Figure 4C), demonstrating that the observed decline in
BrdU+ MuSC is not the result of reduced numbers of satellite
cells but, rather, a functional defect at this age. However, in older
mice (60 weeks), the number of satellite cells is markedly
reduced in aged mdx/mTRG2 mice (Figure 4C), mirroring the
severity of disease progression.
Another measure of MuSC proliferative potential in vivo is an
analysis of clusters of revertant myofibers. Revertant myofibers
express dystrophin protein due to a compensatory mutation in
somatic cells (Hoffman et al., 1990). If the mutation takes place
in a MuSC, upon proliferation, this MuSC will participate in the
regeneration of myofibers in its close proximity, giving rise to
a cluster of dystrophin+ myofibers. We observe a progressive
reduction in revertant myofiber cluster size in successive mdx/
mTR generations, with the median cluster size in mdx/mTRHet,Cmdx/mTRG1, and mdx/mTRG2 declining progressively (Fig-
ure 4D), consistent with a progressive reduction in MuSC prolif-
erative potential.
Critically Shortened Telomeres in Myoblasts
from mdx/mTRG1 and mdx/mTRG2 Mice
Telomeres were analyzed by hybridization of a telomere-specific
probe to metaphase chromosomes by fluorescence in situ
hybridization (telomere FISH). This assay requires large numbers
of mitotic cells in metaphase. Because methods for cultivating
MuSC in sufficient numbers do not yet exist, we analyzed
the derivatives of MuSC, myoblasts, isolated as previously
described (Rando and Blau, 1994). Chromosome ends lacking
detectable telomere repeats (signal-free ends [SFEs]) are
detected at an increased frequency of 49/893 (5.5%) in mdx/
mTRG1 and 34/642 (5.3%) in mdx/mTRG2 mice versus 9/602
(1.5%) in mdx/mTRHet mice (Figures 5A and 5B). The 5%
frequency of SFE seen in mdx/mTRG1 and mdx/mTRG2 mice is
not detected even in highly proliferative organs until later gener-
ations in mice lacking Terc (Blasco et al., 1997), providing evi-
dence that this increased frequency is not due to Terc absence
alone. In addition, in metaphase spreads of myoblasts from
mdx/mTRG1 and mdx/mTRG2 mice, end-to-end chromosomeell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc. 1065
Figure 6. Muscle Stem Cells from mdx/mTRG2
Mice Exhibit Impaired Proliferation In Vitro
(A) Single myofibers were isolated from 8- and 60-week-
old animals and cultured for 96 hr. Representative images
of cultures show a proliferation defect in mdx/mTRG2
muscles, compared to mdx/mTRHet muscles. Scale bar,
50 mm. See also Figure S6.
(B) Graph showing quantification of proliferation capacity
as total number of cells derived per myofiber at 96 hr.
Data are represented as average ± SEM. n = 3; p < 0.05.
(C) Representative images of immunofluorescence stain-
ing of fiber cultures for desmin (green) and nuclei by
Hoechst 33258 (blue). Scale bar, 50 mm.
(D) Graph showing quantification of percentage of des-
min+ cells in cultures derived from single myofibers. Data
are represented as average ± SEM. n = 3; p > 0.05.
(E) Representative images of immunofluorescence stain-
ing of fiber cultures for myosin heavy chain (red) and nuclei
by Hoechst 33258 (blue). Scale bar, 50 mm.
(F) Graph showing quantification of percentage of MyHC+
cells in cultures derived from single myofibers. Data are
represented as average ± SEM. n = 3; p > 0.05.fusions were detected (Figure 5A, arrows), indicating that the
telomere shortening in these cells leads to genomic instability.
In marked contrast, in 602 chromosomes analyzed from mdx/
mTRHet myoblast metaphase spreads, no end-to-end fusions
were detected. SFEs represent chromosome ends with the
shortest telomeres and correlate with an increased incidence
of chromosome fusions and tissue dysfunction in vivo in telome-
rase knockout mice (Chang et al., 2004). This result strongly
supports our hypothesis that exhaustion of proliferative potential
in dystrophicMuSC, via telomere dysfunction, is the direct cause
of muscular dystrophy progression.
Analyses of spleen and testis reveal that these two high-prolif-
erative organs are not affected in the generations analyzed
(Figure S5), which argues against the possibility that the effects
observed are due to the absence of Terc alone and in favor of
a muscle-specific etiology. A scheme depicts the effects of
Terc loss in the etiology of DMD (Figure 5C).
Impaired Proliferation Potential of MuSC
from mdx/mTRG2 mice in Culture
To further test whether the cell-autonomous changes in muscle
tissue were caused by reduced proliferative potential of MuSC in
mdx/mTRG2 mice, we assessed their behavior in vitro. Single
myofibers were isolated from tibialis anterior muscles from1066 Cell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc.8-week-old animals, and the proliferative
potential of MuSC crawling off myofibers was
analyzed after 4 days of culture. Satellite cells
derived from mdx/mTRG2 myofibers exhibit
reduced proliferative potential (261 ± 54 cells/
fiber) compared to mdx/mTRHet myofibers
(586 ± 157 cells/fiber) (Figures 6A and 6B). As
described above (Figure 4C), the number of
satellite cells per myofiber is not altered at this
age, indicating that the observed differences in
cell number result from a cell-autonomous
proliferative defect in MuSC from mdx/mTRG2mice caused by dysfunctional telomeres. The reduction in satel-
lite cell proliferation persists with age; at 60 weeks, satellite cells
frommdx/mTRG2mice give rise only to 40%asmany cells (307 ±
47) as controls (707 ± 37) (Figure 6B).
To assess whether a reduction in the proliferation capacity is
followed by a change in the differentiation efficiency, staining
for desmin and myosin heavy chain, two established myogenic
markers, was performed in vitro. The percentage of desmin+ cells
is not significantly different between mdx/mTRHet (47% ± 8%)
and mdx/mTRG2 myofibers (40% ± 21%), indicating that there
is no impairment in mdx/mTRG2 satellite cells to transition to
myoblasts (Figures 6C and 6D). Of note, with age, the myogenic
potential (desmin expression) is substantially reduced in both
genotypes (Figure 6D), consistentwith previous studies reporting
a decreased myogenic potential in muscle cells from dystrophic
and agedmice (Bockhold et al., 1998; Brack et al., 2007). Myosin
heavy-chain expression shows that spontaneous terminal
differentiation does not differ significantly between mdx/mTRHet
and mdx/mTRG2 cells in young or old mice (Figures 6E and 6F).
These data confirm that satellite cell differentiation properties
do not differ, whereas the proliferative function does. With
increased age, the absolute number of MuSC declines (Fig-
ure 4C), compounding the proliferative defect and leading to an
evenmore pronounced deficit in cells available for muscle repair.
mdx/mTRG2 MuSC Are Impaired in Engrafting
upon Transplantation
To test the combined effects of mdx mutation and telomere
dysfunction on MuSC function in vivo, we assessed the ability
of purified MuSC to engraft and proliferate upon transplantation
into recipient muscles. Freshly isolated MuSC (Sacco et al.,
2008) were infected with a lentivirus expressing GFP, and 3000
cells were transplanted into irradiated tibialis anterior muscles
of immunodeficient NOD/SCID mice (Figure 7A). The infection
efficiency approximated 90% and was not statistically different
among samples (Figure 7B, p > 0.05). Three weeks posttrans-
plantation, mdx/mTRHet MuSC contributed to an average of
200 ± 30 GFP+ myofibers (Figure 7C). Conversely, MuSC iso-
lated from mdx/mTRG2 mice were significantly impaired in their
engraftment capacity, contributing to substantially lower
numbers of myofibers, 81 ± 22 (Figure 7C). These data corrobo-
rate our in vitro analyses and show that MuSC from mdx/mTRG2
mice have a cell-autonomous defect in proliferation that
compromises their ability to generate new muscle fibers in vivo.
To investigate a potential effect of telomere erosion on
myofiber degeneration, we induced acute injury by injection of
notexin in 8-week-old animals and performed histological anal-
yses at day 3 after injury. The extent of muscle damage was
comparable between mdx/mTRHet and mdx/mTRG2, indicating
thatmdx/mTRG2mice are notmore sensitive to this type of tissue
injury (Figure S6). In addition, the infiltrate of hematopoietic
(CD45+ cells), macrophages (CD11b), and lymphocytes (B220)
is equally represented in mdx/mTRHet and mdx/mTRG2 (Fig-
ure S6). These results indicate that mdx/mTRG2mice are compe-
tent to mount an inflammatory response to tissue injury and
provide direct evidence that the hematopoietic compartment is
not compromised. Finally, Sca1+ mesenchymal interstitial cells
and CD31+ endothelial cells are also comparably present in
mdx/mTRHet and mdx/mTRG2 muscle, suggesting that the
severe phenotype is muscle specific and is not the result of func-
tional defects in other cell types.
Amelioration of the Dystrophic Phenotype after
Transplantation of WT MuSC
To test whether the dystrophic phenotype in mdx/mTRG2
mice results from diminished MuSC reserve, we performed
MuSC transplantation experiments into mdx/mTRG2 dystrophic
muscles. Freshly isolated MuSC, either WT or mdx/mTRG2,
were infected with a lentivirus expressing GFP, and 5000 cells
were transplanted into irradiated tibialis anterior muscles of
mdx/mTRG2 mice (Figure 7D). The infection efficiency approxi-
mated 95% and was comparable among groups (p > 0.05;
data not shown). Three weeks posttransplantation, WT MuSC
efficiently engrafted into recipient muscles and contributed to
an average of 299 ± 29 GFP+ myofibers (Figures 7E and 7F
and Figures S7F–S7J), whereas mdx/mTRG2 MuSC contributed
to substantially lower numbers of GFP+myofibers, 118 ± 17 (Fig-
ures 7E and 7F and Figures S7A–S7E). Measurements of fiber
cross-sectional areas indicate that WT MuSC gave rise to larger
myofibers compared to mdx/mTRG2 (Figure 7G), indicating the
ability to more robustly contribute to muscle upon transplanta-
tion. Further histological analysis revealed that the amount of
inflammatory infiltration is substantially reduced in the muscleCregion into which the WT MuSC were injected, compared to
mdx/mTRG2, as evidenced by the low numbers of CD45+ hema-
topoietic cells and overall improvement in tissue architecture
apparent in H&E sections (Figures S7K and S7L). The regenera-
tive potential of transplanted MuSC from control mTRG2 mice
into mdx/mTRG2 animals is similar to that observed with WT
MuSC (data not shown). Together, these results provide strong
evidence that the severe dystrophic phenotype observed in
mdx/mTRG2 mice results from loss of regenerative potential of
endogenous MuSC. Although we cannot completely rule out
the possibility of defects in other cell types or a direct effect on
themyofiber itself as a potential contributing factor, these results
demonstrate that progressive loss ofMuSC reserve plays amajor
role in determining the severity of the dystrophic phenotype.
DISCUSSION
The absence of a mouse model for DMD that faithfully mimics
key features of the human disease has limited our understanding
of its pathophysiology and tests of potential therapies. A long-
standing enigma has been why humans with a dystrophin muta-
tion suffer from such severe muscle wasting, whereas mice with
the same mutation do not. A major difference between humans
and mice is the length of their telomeres, which are substantially
shorter in humans. A reduction in telomere length in MuSC could
severely limit the stem cell pool available for muscle repair over
time. Here, we show that a newmouse model, mdx mice lacking
telomerase activity (mdx/mTR), more closely recapitulates the
DMD phenotype than mouse models described to date, as
evidenced by characteristic severe progressive loss of muscle
form and function.
We postulated that the severe muscle wasting phenotype
observed in this mouse model is due to impaired function of the
MuSC required for damage repair. We ruled out other possible
stem cell etiologies such as premature MuSC differentiation or
a reduction inMuSC numbers permyofiber at the time of disease
onset. Instead, we determined both in vitro and in vivo that the
MuSC frommdx/mTRG2mice suffer from severe defects in prolif-
eration. In vivo,MuSC exhibited reduced division (BrdU labeling),
smaller revertant clone sizes, inability to respond to injury, and
markedly reduced engraftment upon transplantation into mice.
In vitro, the proliferation defect was manifested by a marked
reduction in the number of cells derived from single fibers. This
proliferative defect correlated with an increase in signal-free
chromosome ends and evidence of chromosome fusions nor-
mally not seen in low-turnover tissues such as muscle. Over
time, a decrease in the number of MuSC per muscle fiber was
observed. Presumably, the decrease in MuSC number in aged,
dystrophic telomerase null mice ultimately reflects a failure of
stem cell self-renewal. This reduction in MuSC number exacer-
bates the already impaired regeneration resulting from the
reduced proliferative capacity of the remaining MuSC.
We reasoned that the replicative capacity ofMuSC plays a role
in murine muscle tissue homeostasis, overcoming the defect
observed in human muscle lacking dystrophin. We confirmed
this hypothesis here by coupling the absence of telomerase
together with a constant pressure for muscle cell proliferation
and regeneration caused by the mdx mutation. The result isell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc. 1067
Figure 7. Muscle Stem Cells from mdx/
mTRG2 Mice Exhibit Impaired Engraftment
following Transplantation into Mouse
Muscles
(A) Scheme of transplantation into NOD/SCID
mice.
(B) Representative images of lentivirus-infected
MuSC. Scale bar, 80 mm (left). Graph showing
quantification of infection efficiency expressed
as percentage of GFP+ cells. Data are represented
as average ± SEM (right). p > 0.05.
(C) Three weeks after transplantation, muscles
were harvested, sectioned, and immunostained
for GFP (green), laminin (red), and nuclear Hoechst
(blue). Representative images of transplanted
muscles. Scale bar, 120 mm (left). Graph showing
total numbers of GFP+ myofibers scored per
muscle. Data are represented as average ± SEM.
nR 5; p < 0.01) (right).
(D) Scheme of transplantation into mdx/mTRG2
mice.
(E) Three weeks after transplantation, muscles
were harvested, sectioned, and immunostained
for GFP (green), laminin (red), and nuclear DAPI
(blue). Representative images of transplanted
muscles. Scale bar, 100 mm.
(F) Graph showing total numbers of GFP+ myofib-
ers per muscle. Data are represented as average ±
SEM. n = 5; p < 0.05.
(G) Analysis of GFP+myofiber cross-sectional area
after transplantation shows that WT MuSC give
rise to larger myofibers compared to mdx/mTRG2
MuSC.
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a mouse model, mdx/mTRG2, that closely approximates the
human disease. Muscles from DMD patients have been reported
to have shorter telomeres than those of healthy individuals
(Decary et al., 2000;Mouly et al., 2005). Similarly critical telomere
shortening is evident here in cultured muscle progenitor cells
isolated from mdx/mTRG2 mice with the muscular dystrophy
phenotype. The generation of mouse models lacking telomerase
activity, TERT and Terc knockout mice (Blasco et al., 1997; Liu
et al., 2000), previously resulted in the demonstration that telo-
merase plays a crucial role in self-renewal of adult stem cells in
high-turnover tissues such as blood, liver, skin, and testis
(Allsopp et al., 2003; Lee et al., 1998). By contrast, skeletal
muscle is a stable tissue, and a muscle phenotype in mice
lacking TERT and Terc has never been reported. Even in the
setting of continuous damage, the mdx model, only a mild
muscle phenotype is apparent, and there is no evidence for telo-
mere shortening in myoblasts of these mice. By contrast, we
show here that murine MuSC progeny from mice lacking both
dystrophin and telomerase exhibit a higher frequency of chromo-
somes with signal-free ends (chromosomes with critically short-
ened telomeres), compared to control mdx/mTRHet, indicating
that a persistent need for MuSC proliferation in vivo leads to telo-
mere shortening, consequent senescence-like behavior, and
tissue degeneration. These results provide definitive evidence
that telomerase plays a crucial role in MuSC function in vivo.
Although we cannot entirely rule out an effect of lack of telome-
rase on other cell types or mature myofibers, the findings
highlight a cell-autonomous or intrinsic limitation as causal in
hindering MuSC function.
Our findings of stem cell-autonomous defects are important to
consider in light of recent studies that implicate a primary role of
the environment in maintaining niche function and stem cell
performance. Indeed, these studies show that stem cells from
young and aged mice behave similarly when exposed to
systemic factors from young mice via parabiosis (Brack et al.,
2007; Conboy et al., 2005). Our results show that intrinsic char-
acteristics such as telomere attrition are also critical to muscle
regeneration and need to be taken into consideration when pre-
dicting the effects of modulating the environment on the function
of human MuSC from aged or dystrophic muscles.
The etiology of the fibrosis observed in DMD remains
unknown. Here, we observe that, when WT MuSC are trans-
planted into dystrophic mouse muscles, minimal fibrosis is
observed, whereas fibrosis is extensive when proliferation-
impaired mdx/mTRG2 MuSC are transplanted. These results
are similar to those observed in chronic liver cirrhosis in which
fibrosis and telomere shortening are correlated (Kitada et al.,
1995; Rudolph et al., 2000;Wiemann et al., 2002). These findings
suggest the intriguing possibility that, in chronically injured
tissues, fibrosis is secondary to cell loss, not a primary
competing process that antagonizes repair.
In summary, we provide evidence that telomere shortening is
the result of continuous proliferation in degenerating dystrophic
muscle and describe the generation of a newDMDmousemodel
that more faithfully recapitulates the disease progression in
humans. This model will prove useful for elucidating the
pathophysiology of DMD and for testing potential therapeutic
approaches for this and other muscle wasting diseases, whichChas been hindered by the mild phenotypes that are typical of
currently available mouse models. Our results indicate that
DMD, a muscle degenerative disease, is the result of a multifac-
torial process, due to both a structural defect of the tissue and
progressive exhaustion of its regenerative potential. Therapeutic
interventions should consider both telomere length as well as
myogenic potential of the regenerative cell source in order to
overcome previous limitations (Gussoni et al., 1992). Together,
these data document the importance of telomerase in muscle
homeostasis and provide the first direct experimental evidence
that DMD progression, although initiated and driven by dystro-
phin deficiency, is ultimately a stem cell disease.
EXPERIMENTAL PROCEDURES
Animals
All protocols were approved by the Stanford University Administrative Panel
on Laboratory Animal Care. C57Bl6mdxmice (purchased from Jackson Labo-
ratories) and C57Bl6 mTRHet mice (a kind gift from Ron DePinho) were used to
generate the double-mutant animals. The NOD/SCID-immunodeficient mice
were purchased from the Jackson Laboratories.
Single-Fiber Isolation and Satellite Cell Staining
Single myofibers were isolated from tibialis anterior muscles for all genotypes
as previously described (Collins et al., 2005). See Extended Experimental
Procedures for a detailed description of the procedure.
Force Measurements
Eight-week-old mice were anesthetized and force measurements of lateral
gastrocnemius muscle were performed in vivo on anesthetized animals in
accordance with Stanford guidelines. See Extended Experimental Procedures
for a detailed description of the procedure.
Treadmill Test
The treadmill test was performed using the Exer3/6 (Columbus Instruments).
Mice were acclimated to treadmill running for three times (every other day)
before the test was performed. Mice ran on the treadmill at 20 degrees down-
hill, starting at a speed of 10 meters/min. After 3 min, the speed was increased
1 meter/min to a final speed of 20 meter/min. Exhaustion was defined as the
inability of the animal to remain on the treadmill despite electrical prodding.
SPECT/CT Animal Imaging
Anesthetized (3% isofluorane) animals were placed into SPECT-CT scanner
(Gamma-Medica-Ideas Pre-clinical Imaging) with high-energy resolution
CZT detectors and multipin-hole collimators. See Extended Experimental
Procedures for a detailed description of the procedure.
Irradiation, Cell Transplantation, and Notexin Damage
NOD/SCID and mdx/mTRG2 mice were anesthetized and shielded in a lead-jig
so that only the legs were exposed to the radiation source. A single dose of
18Gy was administered to the legs, and cell transplantation was performed
on the same day. Lentivirus-infected MuSC were resuspended in PBS, and
a 10 ml of cell suspension was injected intramuscularly into the tibialis anterior
(TA) muscles of recipient mice. For local tissue injury, mice were anesthetized
with isofluorane, and a single 10 ml injection of notexin (10 mg/ml, Latoxan,
France) was injected into the TAs of recipient mice.
In Vivo BrdU Labeling
Mice were anesthetized with isofluorane and weighed, and a single dose of
BrdU in PBS was delivered intraperitoneally (100 mg/Kg body weight).
Twenty-four hours later, mice were sacrificed and MuSC isolated, as previ-
ously described (Sacco et al., 2008). After FACS enrichment, MuSC were
cytospun onto slides, fixed, and stained using a BrdU labeling and detection
kit (Roche).ell 143, 1059–1071, December 23, 2010 ª2010 Elsevier Inc. 1069
Telomere Fluorescence In Situ Hybridization
For telomere measurements, primary myoblasts were isolated as previously
described (Rando and Blau, 1994) and maintained in culture in F10/DMEM +
15%FBS+ bFGFmedia. See Extended Experimental Procedures for a detailed
description of the procedure.
Lentiviral Infection
The five plasmid system and infection protocol used here has been previously
described (Westerman et al., 2007). See Extended Experimental Procedures
for a detailed description of the procedure.
Cell Culture
Cells were isolated frommuscle tissue by enzymatic dissociation as described
above. Cells were plated on dishes coated with laminin (Roche) in F10/DMEM
(50/50) + 15%FBS + 2.5ng/ml bFGF (GM) for proliferation and in DMEM + 2%
horse serum (DM) for differentiation.
Image Acquisition of Immunofluorescence and Histology
Images of muscle transverse sections were acquired using an epifluorescence
microscope (Axioplan2, Carl Zeiss MicroImaging, Inc.), Fluar 20X/0.75 objec-
tive lens, and a digital camera (ORCA-ER C4742-95; Hamamatsu Photonics).
The software used for acquisition was OpenLab 4.0.2 (Improvision). Images of
cell cultures were acquired using a laser-scanning confocal microscope
(LSM510, Carl Zeiss MicroImaging, Inc.) using Plan NeoFluar 103/0.3 and
203/0.75 objective lens andmaximumoptical sections with the LSM software.
All images were composed and edited in Photoshop 7.0 (Adobe). Background
was reduced using brightness and contrast adjustments, and color balance
was performed to enhance colors. All of the modifications were applied to
the whole image using Photoshop 7.0 (Adobe).
Statistical Analysis
Data are presented as mean ± SEM. Comparisons between groups used the
Student’s t test assuming two-tailed distributions, with an alpha level of
0.01–0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at doi:10.1016/j.cell.
2010.11.039.
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